PRIME MEDICINE
Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly "search and replace" to restore normal genetic function and address the fundamental causes of disease.
PRIME MEDICINE
Industry:
Biotechnology Genetics Life Science Medical
Founded:
2019-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.primemedicine.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
385 M USD
Technology used in webpage:
Domain Not Resolving HSTS DNSSEC JQuery CDN Microsoft COVID-19 Microsoft Azure Mobile Optimized Drupal Microsoft Azure US East Region
Similar Organizations
Apogee Therapeutics
Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders.
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Cellanome
Cellanome is an integrative multi-omics platform that measures biology through its multi-omics platform.
Colossal Biosciences
Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Inceptive
Inceptive Designs RNA molecules using large-scale deep learning in a tight loop with high-throughput experiments.
MiLaboratories
MiLaboratories is a biotech company developing proprietary software to profile a person's immune picture on a DNA level.
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bristol-Myers Squibb
Bristol-Myers Squibb investment in Corporate Round - Prime Medicine
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Funding Round - Prime Medicine
Casdin Capital
Casdin Capital investment in Series B - Prime Medicine
T. Rowe Price
T. Rowe Price investment in Series B - Prime Medicine
Arrive
Arrive investment in Series B - Prime Medicine
F-Prime Capital
F-Prime Capital investment in Series B - Prime Medicine
Moore Strategic Ventures
Moore Strategic Ventures investment in Series B - Prime Medicine
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Prime Medicine
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Prime Medicine
Samsara BioCapital
Samsara BioCapital investment in Series B - Prime Medicine
Key Employee Changes
| Date | New article |
|---|---|
| 2024-01-05 | Prime Medicine appoints Allan Reine as CFO |
| 2021-10-13 | Prime Medicine Appoints Ann L. Lee as Chief Technical Officer |
Official Site Inspections
http://www.primemedicine.com Semrush global rank: 2.77 M Semrush visits lastest month: 6.65 K
- Host name: 247.154.196.104.bc.googleusercontent.com
- IP address: 104.196.154.247
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Prime Medicine"
Prime Medicine | Delivering on the promise of Prime …
Prime Medicine™ was founded with a goal of transforming the lives of patients with debilitating diseases through the application of our groundbreaking Prime Editing platform and technology.See details»
Patients & Caregivers | Prime Medicine
Current clinical trials. Clinical trials are designed to help determine whether an investigational therapy or treatment is safe and effective. We are currently enrolling patients in Prime-0101, a …See details»
Prime Medicine - Crunchbase Company Profile
Contact Email [email protected] Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly "search and replace" to restore normal …See details»
Prime Medicine, Inc. | LinkedIn
Prime Medicine, Inc. | 18,141 followers on LinkedIn. Delivering on the promise of Prime Editing | Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing ...See details»
Prime Medicine Announces Recent Progress and Highlights 2023 …
As we enter 2023, we look forward to progressing our most advanced programs toward the clinic, while continuing to optimize our technology and build the internal organization, culture and …See details»
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one …See details»
News Release Details - investors.primemedicine.com
Sep 30, 2024 Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb’s Broad Expertise in Development and …See details»
Prime Medicine to Highlight Positive Preclinical Developments …
CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one …See details»
Prime Medicine Appoints Three New Directors to its Board of …
Cambridge, Mass., August 11, 2022 – Prime Medicine, Inc. (“Prime Medicine”), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic …See details»
Prime Medicine becomes the next high-profile biotech to test IPO …
Sep 26, 2022 The startup, which launched last year with $315 million in funding and plans to advance a new form of gene editing, is one of the first big venture-backed biotechs in several …See details»
Prime Medicine Presents First-ever Prime Editing Data in Non …
Oct 27, 2023 “The data presented today are highly encouraging, both for patients and caregivers impacted by GSD1b, as well as for Prime Medicine and the field of gene editing,” said Jeremy …See details»
Prime Medicine Launches with $315 Million Financing to Deliver …
Jul 13, 2021 For more information, visit www.primemedicine.com or LinkedIn. Investor Contact Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 [email protected] Media …See details»
Media | Prime Medicine
7_13_21 The Boston Globe Startup Prime Medicine emerges with $315m to pioneer a new type of gene editing. The Cambridge company was founded by David Liu, a researcher at the Broad …See details»
Prime Medicine to Present Preclinical Data Demonstrating Broad ...
Prime Medicine, Inc.-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative …See details»
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis ...
CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one …See details»
Prime Medicine Announces FDA Clearance of Investigational New …
Apr 29, 2024 First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine’s Ex Vivo Product Candidate Designed to Correct a Prevalent Disease-Causing Mutation of CGD …See details»
Prime Medicine Launches with $315 Million Financing to Deliver …
Company is pioneering true “search and replace” gene editing to address the fundamental genetic causes of disease, restore normal gene function, and potentially provide patients with long …See details»
Prime Medicine's Investment Potential: A Deep Dive Into …
Jan 28, 2024 primemedicine.com. GSD1b’s progress is equally hopeful. ... These filings are integral to switching Prime Medicine from a preclinical organization to an entity with clinical …See details»
Pipeline - Prime Medicine
Learn more about Prime-0101 here, visit clinicaltrials.gov or email us at [email protected] for more information. About PM359. PM359, Prime Medicine’s …See details»